Home World News FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients... World News FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - February 11, 2026 307 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR ΚΑΡΚΙΝΟΣ ΠΝΕΥΜΟΝΑ November 22, 2018 Moxetumomab Approved by FDA for Hairy Cell Leukemia September 14, 2018 Genetic Counseling for Hereditary Breast Cancer: What People With a Family... October 26, 2023 Adding Abiraterone to ADT and Docetaxel Improves Survival in Metastatic Prostate... October 24, 2026 Load more HOT NEWS Woman Discovers Breast Lump in the Shower After Dropping Her Loofah,... 3…2…1…Countdown to Medicare Open Enrollment ESMO awards its first fellowship to support digital and computational pathology Dr Ian Walker on Smoking: ‘An unequal burden, but a fixable...